Combination of Anti α-Gal-PpIX Conjugate and Photodynamic Therapy for the Diagnosis and Elimination of HeLa and CaSki Cells
Keywords:Monoclonal antibody, photodynamic therapy, Human papilloma virus, IgG, LED system.
The photodynamic therapy (PDT) is a specific and alternative treatment for premalignant and malignant diseases. The -Gal epitope is expressed in red blood cells and nucleated cells of placental mammals not primates, but absent in old world monkeys, apes and humans. -Gal epitope has been found in cervical biopsies HPV positive, in biopsies at different stages of cervical intraepithelial neoplasia and in cell lines such as HeLa and CaSki. The aim of this work was to obtain IgG anti a-Gal monoclonal antibody (mAb) and evaluate its usefulness in the photodynamic therapy in order to diagnosis and eliminate infected cells by HPV, types 16 and 18. From the 4C1F6D5G7B8 hybridoma line was obtained a producer hybridoma of IgG3, the mAb was conjugated with PpIX (IgG-PpIX). The IgG-PpIX conjugated was capable of identify the -Gal epitope present at the membrane of HeLa and CaSki cell lines by immunocitochemistry. The cell lines were exposed to IgG-PpIX and irradiated with a LED system at 635 nm at an energy dose of 64.3 J/cm2. The PDT using IgG anti Gal monoclonal antibody has effect on the viability of cervical carcinoma cells; the mortality results obtained were, in descendent order, HeLa (66.9 %) and CaSki (50.8 %). It was possible to conclude that PDT using the immunoconjugate IgG anti -Gal-PpIX is effective to diagnosis and eliminate cervical carcinoma cells.
Schiffman M, Wentzensen N, Wacholder S, Kinney W, Cage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103: 368-83. http://dx.doi.org/10.1093/jnci/djq562
Instituto Nacional de Estadística y Geografía (INEGI) [homepage on the internet].México, DF. [updated 2015 Jan 6; cited 2015 Jun 28]: Available from: http://www.inegi. org.mx/
Tremont-Lukats IW, Ávila JL, Tapia F, Hernández D, Cáceres-Dittmar G, Rojas M. Abnormal expression of galactosyl (alpha1-3) galactose epitopes in squamous cells of the uterine cervix infectes by human papillomavirus. Pathobiol 1996; 64: 239-46. http://dx.doi.org/10.1159/000164054
Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-gal antibody and the Gal?1?3Gal epitope in primates. Proc Natl Acad Sci 1987; 84:1369-73. http://dx.doi.org/10.1073/pnas.84.5.1369
Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes and old world monkeys differ from other mammals in the expression of ?-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263: 17755-62.
Allison RR, Downie GH, Cuenca R, Xin-Hua H, Childs CJH, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis Photodyn Ther 2004; 1: 27-42. http://dx.doi.org/10.1016/S1572-1000(04)00007-9
Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res 2003; 23: 3591-600.
Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011; 61: 250-81. http://dx.doi.org/10.3322/caac.20114
van Dongen GA, Visser GW, Vrouenraets MB. Photosensitizer–antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 2004; 56: 31-52. http://dx.doi.org/10.1016/j.addr.2003.09.003
Hemming AW, Davis NL, Dubois B, Quenville NF, Finley RJ. Photodynamic therapy of squamous cell carcinoma. An evaluation of a new photosensitizing agent, benzoporphyrin derivative and new photoimmunoconjugate. Surg Oncol 1993; 2: 187-96. http://dx.doi.org/10.1016/0960-7404(93)90006-K
Savellano MD, Hasan T. Targeting cells that overexpress the EGF receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem Photobiol 2003; 77: 431-39. http://dx.doi.org/10.1562/0031-8655(2003)077<0431:TCTOTE>2.0.CO;2
Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, van Dongen GA. Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin–monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro. Int J Cancer 2002; 98: 793-8. http://dx.doi.org/10.1002/ijc.10281
Kuimova MK, Bhatti M, Deonarain M, et al. Fluorescence characterisation of multiply-loaded anti- HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy. Photochem Photobiol Sci 2007; 6: 933-9. http://dx.doi.org/10.1039/b708320c
Stuchinskaya T, Moreno M, Cook MJ, Edwards DR, Russell DA. Targeted photodynamic therapy of breast cancer cells using antibody–phthalocyanine–gold nanoparticle conjugates. Photochem Photobiol Sci 2011; 10: 822-31. http://dx.doi.org/10.1039/c1pp05014a
Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res 2005; 65: 6371-9. http://dx.doi.org/10.1158/0008-5472.CAN-05-0426
Hudson R, Carcenac M, Smith K, et al. The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy. Br J Cancer 2005; 92: 1442-9. http://dx.doi.org/10.1038/sj.bjc.6602517
Novichenko NL, Mamchur AA, Lisniak IO, Gamaliya MF. Study of photodynamic efficiency of the hematoporphyrin conjugated with antibody to VEGF in mouse Lewis carcinoma. Exp Oncol 2008; 30: 315-18.
Goff BA, Hermanto U, Rumbaugh J, Blake J, Bamberg M, Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer 1994; 70: 474-80. http://dx.doi.org/10.1038/bjc.1994.330
Hajighasemi F, Khoshnoodi J, Shokri F. Development of two murine monoclonal antibodies recognizing human nG1m(a)-like isoallotypic markers. Hybridoma (Larchmt) 2008; 27: 473-9. http://dx.doi.org/10.1089/hyb.2008.0043
Loirat MJ, Gourbil A, Frioux Y, Muller JY, Blanchard D. A murine monoclonal antibody directed against the Gerbich 3 blood group antigen. Vox Sang 1992; 62: 45-8. http://dx.doi.org/10.1111/j.1423-0410.1992.tb01166.x
Freshney RI. Culture of Animal Cells. A manual of basic technique. New York: Wiley 2000.
Mayo GL, Melendez RF, Kumar N, Mckinnon SJ, Glickman RD. Antibody-targeted photodynamic therapy. Am J Ophtalmol 2003; 136: 1151-2. http://dx.doi.org/10.1016/S0002-9394(03)00675-5
Prasad PN. Introduction to Biophotonics. New Jersey: Wiley 2003. http://dx.doi.org/10.1002/0471465380
Klotz LO, Fritsch C, Briviba K, Tsacmacidis N, Schliess F, Sies H. Activation of JNK and p38 but not ERK MAP kinases in human skin cells by 5-aminolevulinate-photodynamic therapy. Cancer Res 1998; 58: 4297-300.
Castillo-Millán J. Induced cytotoxicity in breast cancer by photodynamic therapy with high-power LED’s. Rev Cub Fis 2010; 27: 263-6.
Adamopoulou M, Kalkani E, Charvalos E, Avgoustidis D, Hairdopoulos D, Yapijakis C. Comparision of cytology, colposcopy, HPV typing and biomarker analysis in cervical neoplasia. Anticancer Res 2009; 29: 3401-10.